Sandoz Canada intros 2 hypertension generics
Sandoz Canada is bringing Canadian patients two new generics to treat hypertension. The Boucherville, Quebec-based company is introducing generic Coversyl (perindopril erbumine) and generic Coversyl Plus (perindopril erbumine/indapamide).
“We are very pleased to be bringing cost-effective generic alternatives to these important medicines to Canadians across the country,” Sandoz Canada president and general manager Michel Robidoux said. “[These products] will help to make high-quality treatment more accessible to Canadians and could save the health care system millions of dollars every year through prescription of high-quality, cost-effective generics.”
Sandoz Canada’s generic Coversyl is an ACE inhibitor indicated to treat mild-to-moderate hypertension and congestive heart failure in adults. It will be available in 2-, 4- and 8-mg dosage strength tablets. The generic Coversyl Plus includes the addition of diuretics. It will be available in tablets with dosage strengths of 2 mg/0.625 mg, 4 mg/1.25 mg and 8 mg/2.5 mg.
CVS Health’s ScriptPath wins PBMI Excellence Award
The Pharmacy Benefit Management Institute has awarded CVS Health its 2018 Excellence Award for its ScriptPath Prescription Schedule. Rolled out last fall, the prescription schedule is designed to offer patients a consolidated view of their current prescriptions that outlines when and how to take each prescribed medication.
“We are pleased to be recognized with this award for our industry-leading work to bring the ScriptPath Prescription Schedule to patients as we help them on their path to better health,” CVS Health chief medical officer Troyen Brennan said. “For CVS Health, this award validates our efforts to develop innovative programs that improve patient engagement and medication adherence, better manage chronic diseases like diabetes and help clients keep their health care costs down.”
CVS Health said that studies have found that patients see a decrease in adherence between 5.7% and 6.8% for each dose added to their medication regimen, and that hospital readmission rates increase by as much as 69% for patients who don’t adhere to their therapies — to the tune of $100 billion to $300 billion in healthcare costs. The ScriptPath Prescription Schedule was designed to use the proprietary Clinical Engine to review a patient’s medications, creating a schedule that divides the medications into as many as four dosing times per day.
The prescription schedule also marks the first in a series of ScriptPath efforts that CVS Pharmacy is undertaking. This spring, it is bringing patients the ScriptPath Prescription Label and Prescription Overview, the company said.
Hikma brings on former Teva generics leader as CEO
Generics maker Hikma Pharmaceuticals has brought on Sigurdur Olafsson as its CEO, effective immediately. Olafsson brings to the position more than 25 years of pharmaceutical industry experience, including his two years as president and CEO of global generic medicines at Teva from 2014 to 2016.
“We are delighted that Siggi is joining Hikma as our new CEO,” said Said Darwazah, who will transition to executive chairman from his current role as chairman and CEO. “He brings a wealth of pharmaceutical and leadership experience and we are confident that his deep sector knowledge, paired with his proven ability to drive growth, will help us achieve our ambitions for the business.”
In his role, Olafsson will oversee development and execution of Hikma’s corporate strategy with a focus on growth opportunities. In his new role, Darwazah will oversee and guide the CEO in exeuting his strategic vision for the company, as well as optimize the company’s long-term potential, Hikma said.
“I am looking forward to leading the Hikma team, building on the strong legacy the business has established, particularly in the U.S. and MENA,” Olafsson said.. “I share Said’s confidence in the future of this business, and believe that we have the potential to deliver substantial value to our customers, employees, investors and the wider community.”
Olafsson is set to join Hikma’s board of directors, subject to election at its next meeting in May 2018.
“I am very pleased that Siggi is joining Hikma,” Hikma senior independent non-executive Robert Pickering said. “This is a pivotal time for Hikma as we embark on our next chapter. The Board and I are confident that Siggi and Said, working together, will significantly enhance our ability to execute our strategy and deliver long-term sustainable growth.”